ELVN
NASDAQ HealthcareEnliven Therapeutics, Inc. - Common Stock
Biotechnology
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
๐ Market Data
| Price | $45.41 |
|---|---|
| Volume | 111,896 |
| Market Cap | 3.33B |
| Beta | 0.240 |
| RSI (14-Day) | 11.0 Oversold |
| 200-Day MA | $39.47 |
| 50-Day MA | $56.00 |
| 52-Week High | $62.32 |
| 52-Week Low | $14.79 |
| Forward P/E | -19.41 |
| Price / Book | 3.71 |
๐ฏ Investment Strategy Scores
ELVN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (61/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ELVN in your text
Paste any article, transcript, or post โ the tool will extract ELVN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-24.